Teleflex's NeoTract reports results of UroLift System prostate treatment
Teleflex's wholly owned subsidiary NeoTract presented new clinical data at the 2018 Annual Meeting of the Northeastern Section of the American Urology Association in Toronto, from a study of the company's UroLift System for patients with Benign Prostatic Hyperplasia. The real-world study evaluated the UroLift System treatment for lower urinary tract symptoms in men with BPH. The study analyzed outcomes from patients to examine how the UroLift System performs in a real-world setting and whether outcomes are similar to those seen in clinical studies. Data from the study showed a 62% improvement in International Prostate Symptom Score two months after treatment. These changes are statistically better than the pivotal L.I.F.T trial results. Several recent single-center studies have established that results from the L.I.F.T clinical study are being replicated by investigators in the real world.